Kuros Biosciences: Completion of the Acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals Triggers a $5 Million Milestone Payment
02 juin 2022 01h00 HE
|
Kuros Biosciences
Ad-hoc announcement pursuant to Article 53 of the SIX listing rules • $2.5 million of milestone to be paid to XOMA Corporation under royalty agreement SCHLIEREN (ZURICH), Switzerland, June 02,...
Kuros Biosciences’s MagnetOs Granules Cleared by FDA for Expanded Spinal Indications
03 févr. 2022 01h00 HE
|
Kuros Biosciences
Rare clearance for bone graft for standalone use in spine based on human clinical dataClearance attained with evidence from Level 1 randomized controlled trialPositions MagnetOs above most other...
Kuros Biosciences Reports Continued Increase in MagnetOs U.S. Sales
26 oct. 2021 01h00 HE
|
Kuros Biosciences
MagnetOs U.S. YTD sales increase 119% in 2021 compared to 2020Kuros expanding MagnetOs range to increase perioperative solutions for surgeons SCHLIEREN (ZURICH), Switzerland, Oct. 26, 2021 (GLOBE...
Kuros Biosciences to Showcase New MagnetOs Products at NASS 2021 Annual Meeting
28 sept. 2021 01h00 HE
|
Kuros Biosciences
New products expand perioperative solutions for surgeonsData to be presented on new formulation of MagnetOs that includes a collagen carrier SCHLIEREN (ZURICH), Switzerland, Sept. 28, 2021 (GLOBE...
Kuros to receive $7 million up front and potentially $166.5 million in future revenues under a royalty purchase agreement with XOMA related to Kuros’s license agreement with Checkmate Pharmaceuticals
15 juil. 2021 04h17 HE
|
Kuros Biosciences
SCHLIEREN (ZURICH), Switzerland, July 15, 2021 (GLOBE NEWSWIRE) -- Kuros Biosciences AG (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today that it has...
Kuros Biosciences Reports Results for the Full Year 2020
18 mars 2021 02h00 HE
|
Kuros Biosciences
Financial highlights CHF 29.8 million cash & cash equivalents, trade and other receivables at December 31, 2020Revenues increased by 58% to CHF 4.0 million Operational highlights Initiated...
Kuros Biosciences to Present at Upcoming Clinical and Investor Conferences
10 mars 2021 01h00 HE
|
Kuros Biosciences
New data on the role of osteoimmunology in bone formation at BritSpine MeetingInvestor presentation at BioCapital Europe SCHLIEREN (ZURICH), Switzerland, March 10, 2021 (GLOBE NEWSWIRE) -- Kuros...
Kuros Biosciences Announces MagnetOs Sales and Distribution Agreements Across Northern Europe
02 mars 2021 01h00 HE
|
Kuros Biosciences
Agreements in Netherlands, Switzerland and Austria and letter of intent in FinlandSupports further acceleration of sales of MagnetOs bone graft SCHLIEREN (ZURICH), Switzerland, March 02, 2021 ...
CORRECTING AND REPLACING -- Kuros Biosciences’s Licensee Checkmate Pharmaceuticals Completes its IPO on NASDAQ
09 sept. 2020 13h43 HE
|
Kuros Biosciences
SCHLIEREN (ZURICH), Switzerland, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Kuros Biosciences corrects gross proceeds raised in first bullet point and second paragraph to $75 million from $86.25 million....
Kuros Biosciences’s licensee Checkmate Pharmaceuticals completes its IPO on NASDAQ
09 sept. 2020 01h00 HE
|
Kuros Biosciences
Total gross proceeds raised by Checkmate in IPO of $86.25 million (including sale of overallotment shares)Intention to use part of the net proceeds from the IPO to fund the development of its product...